Announcements Trials

Browse Landscape

Phase

Phase NA 10 Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Sarcopenia 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pharyngeal Neoplasms 1 Obesity 1 Neoplasms 1 Motor Activity 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Laryngeal Neoplasms 1 Hematopoietic and Lymphatic System Neoplasm 1 Head and Neck Neoplasms 1

Interventions

Docetaxel 137 Prednisone 120 Abiraterone Acetate 91 Leuprolide 86 enzalutamide 84 Radiotherapy 59 bicalutamide 56 Magnetic Resonance Spectroscopy 54 Goserelin 54 Androgen Antagonists 51 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 47 apalutamide 44 abiraterone 34 Radiosurgery 31 Specimen Handling 30 gallium 68 PSMA-11 29 Gonadotropin-Releasing Hormone 29 cabazitaxel 28 Carboplatin 27 darolutamide 26 Estramustine 24 luprolide acetate gel depot 23 relugolix 22 Metformin 22 Triptorelin Pamoate 20 sipuleucel-T 19 radium Ra 223 dichloride 19 Radiation 19 pembrolizumab 18 deltacortene 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Prostatic Neoplasms × Resistance Training × Clear all

NCT06271551 2024-02-21

ESTRACISE

Central Finland Hospital District

Phase 2 Not yet recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡